NC 1461
Latest Information Update: 02 May 2008
At a glance
- Originator Neurochem
- Developer BELLUS Health
- Class
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Seizures; Type 2 diabetes mellitus
Most Recent Events
- 02 May 2008 Discontinued - Preclinical for Seizures in Canada (unspecified route)
- 07 Jul 2006 No development reported - Preclinical for Seizures in Canada (unspecified route)
- 26 Aug 2003 Discontinued - Preclinical for Type-2 diabetes mellitus in Netherlands (unspecified route)